Navigation Links
Neurobiological Technologies Sets Date for First Quarter Financial Results
Date:11/4/2008

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

Live Call:

-- Date: Thursday, November 6, 2007

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 800-309-1245 (U.S.) 719-457-2080 (International)

Webcast of Call:

-- A live webcast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: (Archived for 90 days)

A playback of the conference call will be available from 1:30 PM November

6 (ET) through midnight November 13 (ET).

Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820

(international).

Replay access code: 8094663.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
3. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
6. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies CEO to Retire on December 31, 2008
8. Neurobiological Technologies Reports Third Quarter Financial Results
9. Neurobiological Technologies Sets Date for Third Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic Information for ... Discovery --> --> The ... sequence 100,000 individuals. It is intended to initially include populations ... North and East Asian countries. --> ... focus on creating phased reference genomes for all major Asian ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit ... are researched, developed, marketed and made accessible to patients around ... Open had named the publication of the Good ... The publication is also featured as one of BMJ ... the last year that are most frequently read. ...
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products ... Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, ...
Breaking Biology Technology:
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):